Page 10 - Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG

Systemic therapies: Enzalutamide

• Enzalutamide (160 mg/day) is a treatment option regardless of volume of

disease (Level 1, Strong recommendation)

• Enzalutamide should not be used in combination with docetaxel (Level 2,

Strong recommendation)

• Enzalutamide may be considered in mCSPC patients previously treated

with docetaxel chemotherapy (Level 1, Weak recommendation)

mCSPC: metastatic castration-sensitive prostate cancer